DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Evoxac (Cevimeline Hydrochloride) - Summary

 
 



EVOXAC SUMMARY

Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts.

Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjögren’s Syndrome.


See all Evoxac indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Evoxac (Cevimeline)

Sjogren's Syndrome
Source: MedicineNet Bad Breath Specialty [2017.06.30]
Title: Sjogren's Syndrome
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 6/30/2017 12:00:00 AM

Sjogren's Syndrome Symptoms, Signs, and Diagnosis
Source: MedicineNet Antinuclear Antibody Specialty [2017.01.31]
Title: Sjogren's Syndrome Symptoms, Signs, and Diagnosis
Category: Doctor's & Expert's views on Symptoms
Created: 8/31/2011 12:00:00 AM
Last Editorial Review: 1/31/2017 12:00:00 AM

more news >>

Published Studies Related to Evoxac (Cevimeline)

Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia. [2012]
of life (QOL) in patients with xerostomia... CONCLUSIONS: Xerostomia is a significant sequela of treatment of head and neck

Comparison of the effects of pilocarpine and cevimeline on salivary flow. [2009.05]
OBJECTIVE: The aim of the present study was to compare the effect of low-dose pilocarpine and cevimeline as stimulants for salivary flow in healthy subjects... CONCLUSION: Both drugs showed efficacy in increasing the salivary flow in healthy volunteers, but cevimeline was more effective than pilocarpine.

Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study. [2013]
and pilocarpine in the secretion of saliva in patients with xerostomia... CONCLUSION: Both medications increased the secretion of saliva at the end of four

Cevimeline (Evoxac (R)) overdose. [2011.03]
Cevimeline (Evoxac (R)) is an oral muscarinic agent that has been recently approved for the treatment of xerostomia in the setting of Sjogren's syndrome.

Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations. [2010.01.04]
The objective of the present work is to develop an extended-release dosage form of cevimeline. Two types of extended-release tablets (simple matrix tablets and press-coated tablets) were prepared and their potential as extended-release dosage forms were assessed...

more studies >>

Clinical Trials Related to Evoxac (Cevimeline)

Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia [Completed]
The purpose of this study is to determine the effectiveness of cevimeline (versus placebo) on the oral health of patients who have dry mouth which was caused by radiation therapy that was given for treatment of head and/or neck cancer.

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions [Completed]
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions [Completed]
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions

Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva [Completed]
The main objectives were: 1) To determine the efficacy of both cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia, and 2) To compare the side-effects between the treatment for xerostomia with cevimeline and with pilocarpine.

Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer [Completed]
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of cevimeline in treating patients who have dryness of the mouth caused by radiation therapy for head and neck cancer.

more trials >>

Reports of Suspected Evoxac (Cevimeline) Side Effects

Hyperhidrosis (2)Abdominal Pain Upper (2)Localised Infection (2)Weight Decreased (1)Deafness (1)Drug Interaction (1)Headache (1)Chronic Obstructive Pulmonary Disease (1)Fatigue (1)Palpitations (1)more >>


Page last updated: 2017-06-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017